Explore
Trendline
Puma Biotechnology Raises 2026 Revenue Guidance Amid Increased Demand for NERLYNX
Puma Biotechnology Raises 2026 Revenue Guidance Amid Increased Demand for NERLYNX
Read More
Trendline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Read More
Trendline
Verastem Oncology Reports Financial Results and Initiates New Cancer Trials
Verastem Oncology Reports Financial Results and Initiates New Cancer Trials
Read More
Trendline
Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline
Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline
Read More
Trendline
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Read More
Trendline
DiaMedica Therapeutics Reports Financial Results and Advances Clinical Trials for Preeclampsia and Stroke
DiaMedica Therapeutics Reports Financial Results and Advances Clinical Trials for Preeclampsia and Stroke
Read More
Trendline
Zura Bio Reports Strong Financial Position and Progress in Clinical Trials
Zura Bio Reports Strong Financial Position and Progress in Clinical Trials
Read More
Trendline
Soligenix Reports Financial Results and Updates on Clinical Trials
Soligenix Reports Financial Results and Updates on Clinical Trials
Read More
Trendline
Soligenix Reports Financial Results and Strategic Updates Amid Clinical Trial Challenges
Soligenix Reports Financial Results and Strategic Updates Amid Clinical Trial Challenges
Read More
Trendline
BioLife Solutions Reports 25% Revenue Growth in Q1 2026, Driven by Cell and Gene Therapy Market
BioLife Solutions Reports 25% Revenue Growth in Q1 2026, Driven by Cell and Gene Therapy Market
Read More
Trendline
Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones
Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones
Read More
Trendline
Pfizer Maintains 2026 Guidance Amid Patent Expiration Challenges
Pfizer Maintains 2026 Guidance Amid Patent Expiration Challenges
Read More